Kolexia
Egreteau Joelle Oncologie médicale
Egreteau Joelle
Oncologie médicale
Hôpital du Scorff
Lorient, France
43 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du côlon Tumeurs colorectales Adénocarcinome Métastase tumorale Tumeurs de l'estomac Tumeurs de l'oesophage Tumeurs du foie Tumeurs du rectum Tumeurs du sein

Collaborateurs

Voir plus
Bouche Olivier
Bouche Olivier
Hôpital Robert-Debré Reims, Reims, France
Faroux Roger
Faroux Roger
Centre Hospitalier Départemental Vendée, La Roche-sur-Yon, France
Taieb Julien
Taieb Julien
Hôpital Européen Georges Pompidou, Paris, France
Cumin Isabelle
Cumin Isabelle
Hôpital du Scorff, Lorient, France

Industries

Voir plus
Sanofi
1 collaboration(s)
Dernière en 2020
Pierre Fabre
1 collaboration(s)
Dernière en 2022
ESTEVE PHARMACEUTICALS S.A.S
1 collaboration(s)
Dernière en 2023
AstraZeneca
1 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
IDEA: A Phase III Randomized Trial Investigating the Duration of Adjuvant Therapy(3 Versus 6 Months) With the Modified FOLFOX 6 or XELOX Regimens for Patients With Stage III Colon Cancer
Essai Clinique (GERCOR (Multidisciplinary Group in Oncology))   27 septembre 2023
POCHI: Pembrolizumab in Combination With Xelox Bevacizumab in Patients With Microsatellite Stable Mestatic Colorectal Cancer and a High Immune Infiltrate : a Proof of Concept Study
Essai Clinique (Fédération Francophone de Cancérologie Digestive)   16 août 2023
The place of the relative at the time of the announcement of cancer progression: BABEL - a mixed-methods study.
Palliative & supportive care   26 juin 2023
Perioperative Cetuximab with Cisplatin and 5-Fluorouracil in Esogastric Adenocarcinoma: A Phase II Study.
Cancers   06 avril 2023
Aflibercept-LV5FU2 as first-line treatment of non-resectable metastatic colorectal cancers: Results of the FOLFA randomized phase II trial.
2022 ASCO Annual Meeting I   02 juin 2022
Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Analysis of the PRODIGE-GERCOR IDEA-France Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research   03 juin 2021
444P PRODIGE 25 (FFCD 11-01)-FOLFA: A randomized phase II trial evaluating aflibercept associated with LV5FU2 regimen as first-line treatment of non-resectable metastatic colorectal cancers
Abstract Book of the ESMO Virtual Congress2020 19 – 21 September / 16 – 18 October 2020   01 septembre 2020
Combination Chemotherapy and Bevacizumab With or Without Bevacizumab Maintenance Therapy in Treating Patients With Metastatic Colorectal Cancer: Multicenter Phase III Randomized Study of FOLFIRI Plus Bevacizumab Following or Not by a Maintenance Therapy With Bevacizumab in Patients With Non-Pretreated Metastatic Colorectal Cancer
Essai Clinique (Fédération Francophone de Cancérologie Digestive)   27 mars 2020
Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial.
British journal of cancer   04 février 2020
Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration
Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September – 1 October 2019, Barcelona, Spain   01 octobre 2019